10,905 Shares in Corcept Therapeutics Incorporated (NASDAQ:CORT) Bought by Atlas Capital Advisors Inc.

Atlas Capital Advisors Inc. bought a new stake in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 10,905 shares of the biotechnology company’s stock, valued at approximately $550,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Kestra Investment Management LLC bought a new position in Corcept Therapeutics during the 4th quarter valued at approximately $27,000. National Bank of Canada FI bought a new position in shares of Corcept Therapeutics during the fourth quarter valued at $42,000. USA Financial Formulas purchased a new position in shares of Corcept Therapeutics in the 4th quarter worth about $54,000. Newbridge Financial Services Group Inc. bought a new position in Corcept Therapeutics in the 4th quarter worth about $58,000. Finally, Principal Securities Inc. grew its position in Corcept Therapeutics by 63.6% during the 4th quarter. Principal Securities Inc. now owns 1,243 shares of the biotechnology company’s stock valued at $63,000 after purchasing an additional 483 shares during the last quarter. 93.61% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Corcept Therapeutics news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the company’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $68.08, for a total value of $149,776.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Sean Maduck sold 100,000 shares of the company’s stock in a transaction on Monday, March 31st. The stock was sold at an average price of $100.54, for a total transaction of $10,054,000.00. Following the completion of the transaction, the insider now directly owns 85,622 shares of the company’s stock, valued at $8,608,435.88. This represents a 53.87 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 163,124 shares of company stock worth $15,074,318 over the last quarter. 20.50% of the stock is currently owned by corporate insiders.

Corcept Therapeutics Stock Performance

Shares of CORT opened at $74.45 on Friday. The firm has a market capitalization of $7.85 billion, a P/E ratio of 59.09 and a beta of 0.14. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.70 and a quick ratio of 3.64. Corcept Therapeutics Incorporated has a one year low of $20.84 and a one year high of $117.33. The business has a fifty day moving average of $64.81 and a 200 day moving average of $56.28.

Corcept Therapeutics (NASDAQ:CORT) last announced its earnings results on Wednesday, February 26th. The biotechnology company reported $0.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.37 by ($0.11). Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%. The business had revenue of $181.89 million for the quarter, compared to the consensus estimate of $200.12 million. As a group, sell-side analysts anticipate that Corcept Therapeutics Incorporated will post 1.36 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on CORT shares. StockNews.com downgraded shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, February 28th. HC Wainwright upped their price objective on Corcept Therapeutics from $115.00 to $150.00 and gave the company a “buy” rating in a research report on Monday, March 31st. Truist Financial lifted their target price on Corcept Therapeutics from $76.00 to $150.00 and gave the stock a “buy” rating in a report on Monday, March 31st. Canaccord Genuity Group upped their price target on Corcept Therapeutics from $130.00 to $142.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Piper Sandler lifted their price objective on Corcept Therapeutics from $128.00 to $131.00 and gave the stock an “overweight” rating in a report on Thursday. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $143.25.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.